E-SENSE is a MedTech startup transforming the management of emergent and chronic organ disease through scalable, artificial intelligence (AI)-driven multimodal biomedical imaging. Guided by a science-to-business (S2B) philosophy, the company’s innovations are rooted in rigorous research and clinical validation. Its flagship product, VitoCheck, integrates AI with proprietary electrical impedance tomography to deliver real-time, non-invasive, radiation-free assessments of heart, lung, liver, and kidney health. This technology enables affordable, accessible screening across clinical, community, and home settings, helping to bridge healthcare gaps in underserved regions. In 2025, E-SENSE was named Tech Impact Company of the Year at the Tech Fest Hong Kong Awards and received the Gold Medal with Jury Congratulations at the 50th International Exhibition of Inventions of Geneva.